Research programme: inflammation therapeutics - Evotec

Drug Profile

Research programme: inflammation therapeutics - Evotec

Latest Information Update: 14 Jan 2010

Price : $50

At a glance

  • Originator Evotec AG
  • Class
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MAP-kinase-activated kinase 2 inhibitors; Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 21 May 2007 Early research in Inflammation in Germany (unspecified route)
  • 21 May 2007 Inflammation programme is available for licensing worldwide (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top